BIOD Share Price

Open 0.68 Change Price %
High 0.71 1 Day 0.04 6.56
Low 0.52 1 Week 0.00 0.00
Close 0.65 1 Month 0.00 0.00
Volume 2338156 1 Year 0.35 116.67
52 Week High 0.80
52 Week Low 0.22
BIOD Important Levels
Resistance 2 0.83
Resistance 1 0.75
Pivot 0.63
Support 1 0.55
Support 2 0.47
NASDAQ USA Most Active Stocks
SIRI 4.30 -5.49%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
QQQ 115.67 0.17%
WRES 0.09 0.00%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PERF 1.90 22.58%
ASNA 7.01 20.24%
SBSA 4.60 17.95%
CEMP 7.55 15.27%
XXIA 15.55 14.76%
More..
NASDAQ USA Top Losers Stocks
PTIX 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OPXAW 0.01 -50.00%
VALV 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Biodel Inc. (NASDAQ: BIOD)

BIOD Technical Analysis 4
As on 3rd Nov 2016 BIOD Share Price closed @ 0.65 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 0.37 & Buy for SHORT-TERM with Stoploss of 0.50 we also expect STOCK to react on Following IMPORTANT LEVELS.
BIOD Target for December
1st Target up-side 0.75
2nd Target up-side 0.83
3rd Target up-side 0.9
1st Target down-side 0.55
2nd Target down-side 0.47
3rd Target down-side 0.4
BIOD Other Details
Segment EQ
Market Capital 38872256.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.biodel.com
BIOD Address
BIOD
100 Saw Mill Road
Danbury, CT 06810
United States
Phone: 203-796-5000
Fax: 203-796-5001
Interactive Technical Analysis Chart Biodel Inc. ( BIOD NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Biodel Inc.
BIOD Business Profile
Biodel Inc. (Biodel) is a development-stage speciality biopharmaceutical company focused on the development and commercialization of treatments for diabetes. The Company develops its product candidates by applying its formulation technologies to existing drugs. Its advanced program involves developing formulations of injectable recombinant human insulin (RHI). In addition to its ultra-rapid-acting insulin formulations, the Company has developed prototype formulations of a liquid glucagon, a basal insulin and a glucose responsive insulin, in each case for use by patients with diabetes. RHI-based formulation known as Linjeta was the subject of a New Drug Application (NDA).